FTC

October 02, 2024

Andrea Beaty

Blog Post Anti-MonopolyCorporate CrackdownFTC

In Spite Of Limited Resources, FTC Keeps Calling Out Would-Be Oil Price Fixers

FTC Chair Lina Khan has explicitly called for more resources to investigate oil and gas mergers, as current funding and staffing levels are forcing the agency to “make difficult decisions” on how to pursue enforcement in oil and gas markets. How many more anti-competitive business practices could the agency unveil with more time and funding?

September 25, 2024

Andrea Beaty

Blog Post Corporate CrackdownFTCHousing

FTC’s Crackdown On Invitation Homes Highlights Corporate Landlords’ Exploitation Of Tenants

Yesterday, the Federal Trade Commission took enforcement action against Invitation Homes, the country’s largest single-family home landlord. It’s an action that not only identifies corporate malfeasance as a key source of the sky-high rent prices tenants are facing, but one that also sends a warning shot to other corporate landlords to quit using such practices – with the potential larger impact of lowering rental prices.

September 24, 2024

KJ Boyle

Blog Post Anti-MonopolyEconomic MediaFTC

Khan’s Prime-Time Interview Dispels Corporate America’s Concerns Raised By Lesley Stahl

On Lina Khan’s 60 Minutes interview with CBS’s Lesley Stahl, the FTC Chair told the nation about the agency’s many successes during the Biden administration. They discussed successful FTC’s actions to bring down inhaler, insulin and other drug costs, pending lawsuits against Amazon and other Big Tech giants, and Khan’s chilling effect on corporate willingness to pursue anti-competitive mergers. While Stahl espoused corporate America’s ‘fear’ of Khan’s leadership, the FTC Chair proudly stood by the agency’s actions to protect Americans from corporate monopolies.

January 26, 2024

KJ Boyle

Blog Post Anti-MonopolyFTCPharma

The FTC Ain’t Nothin to Mess With

The FTC has won its lawsuit against Martin Shkreli, the pharmaceutical executive infamous for jacking up the price of the antiparasitic drug Daraprim from $13.50 to $750 overnight in 2015 and later using his ill-gotten fortune to buy an exclusive Wu-Tang Clan album for $2 million. Shkreli is the quintessential corporate ghoul, having already racked up convictions for securities fraud—which resulted in an indefinite ban from the securities industries—and failure to pay $1.26 million in New York state taxes. Now, his price gouging has finally caught up with him, as the FTC successfully argued that he spearheaded an anti-competitive scheme to monopolize the drug. The presiding judge found Shkreli’s conduct to be “egregious, deliberate, repetitive, long-running, and ultimately dangerous,” issuing a $64.6 million fine and imposing a lifetime ban from the pharmaceutical industry. 

August 02, 2023 | Revolving Door Project Newsletter

Andrea Beaty

Newsletter Anti-MonopolyCongressional OversightDepartment of JusticeFTCGovernment Capacity

Following Failed Hearing, Jim Jordan And Republicans Try New Tacks To Take Down Khan and Kanter

Two weeks ago, Federal Trade Commission (FTC) Chair Lina Khan entered a House Judiciary  Committee hearing with a target on her back. In the leadup to the hearing, Republicans readied their trumped-up attacks against Khan and the agency she leads: a barely relevant memo from a conflicted ethics officer, a list of unfounded grievances from bitter former Commissioner Christine Wilson, and absurd defenses of Elon Musk’s lazy privacy practices at Twitter. But Khan emerged unscathed, and by the end, the Republicans had lost all their fire.